Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

  • STATUS
    Recruiting
  • End date
    Aug 13, 2023
  • participants needed
    16
  • sponsor
    Baylor College of Medicine
Updated on 13 April 2021
hearing loss
bisphosphonate
bone mineral density
col1a2
birth control method
col1a1
dentinogenesis imperfecta
rare disorder
fresolimumab

Summary

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. OI can range from very severe to very mild. The current standard-of-care for severe types of OI involves the use of IV medications (bisphosphonates) and surgery to put rods in bones to strengthen them. These therapies, although often life-saving, are new and very little is known about their long-term effects on bone and other body systems.

Transforming growth factor beta (TGF-) is a protein important in bone formation. Fresolimumab is an antibody that can silence TGF- . In studies with mice with OI, it has been shown that silencing TGF- can lead to higher bone mass, quality and strength. The purpose of this study is to determine if fresolimumab is safe in the treatment of OI.

Description

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. OI can range from very severe to very mild. Individuals with the most severe type of OI may die at birth. People with severe OI who survive may have bowed arms and legs, very short stature and be unable to walk. People with the mildest form of OI may only break bones occasionally and have normal height and lifespan. Breaks can occur in any bone, but are most common in the arms and legs. The current standard-of-care for severe types of OI involves the use of IV medications (bisphosphonates) and surgery to put rods in bones to strengthen them. These therapies, although often life-saving, are new and very little is known about their long-term effects on bone and other body systems.

TGF- is a protein important in bone formation. Studies have shown that increased TGFactivity leads to lower bone mass and strength and increased fractures. Fresolimumab is an antibody that can silence TGF- . In studies with mice with OI, it has been shown that silencing TGF- can lead to higher bone mass, quality and strength.

Details
Condition Osteogenesis Imperfecta, Collagen disease, Collagen Vascular Diseases, Collagen Vascular Diseases, brittle bones
Treatment Fresolimumab
Clinical Study IdentifierNCT03064074
SponsorBaylor College of Medicine
Last Modified on13 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Willing and able to provide signed informed consent
Are 18 years or older
Have a diagnosis of moderate-to-severe OI based on various clinical features
Have genetic mutations that include glycine substitution in COL1A1 or COL1A2, or pathogenic variants in CRTAP, PPIB, or LEPRE1 (if genetic information is unavailable at screening, this may be assessed at screening visit on a clinical or research basis)
Females of child-bearing potential must have a negative urine pregnancy test, agree to and have the ability to use acceptable birth control method for entire duration of the study
For Males enrolled in the study, partners must agree to use an acceptable form of birth control for the entire duration of the study

Exclusion Criteria

Fracture less than 3 months prior to the screening visit
Rodding or instruments that prevents reliable bone mineral density (BMD) assessment
Have a known unhealed fracture involving a long bone
Do not meet laboratory safety requirements such as: Vitamin D < 15 ng/dL Serum albumin-corrected calcium levels below 8 mg/dL, Hemoglobin < 10 g/dL, Platelet count < 75,000mm3;, Prothrombin time/(PT/INR) international normalized ratio > 1.5 times Upper Limit of Normal (ULN), Clinical or laboratory abnormality of Grade III or higher as assessed by CTCAE v4.0 which in the view of investigator would compromise safety
Have an EKG with QTc of > 450 ms
Have a known allergy to fresolimumab
Have current clinically significant infection
Have a personal history of basal cell carcinoma, squamous cell carcinoma or keratoacanthomas, a personal history of cancer, recent or remote
Have evidence of untreated cavities or planned invasive dental work during the study period
Have had organ transplantation
Have known or suspected valvular heart disease
Plan to have skeletal surgery in the study period
Have had osteotomy 5 months prior to the screening visit
Being treated with zoledronic acid or pamidronate less than 12 months of screening OR oral bisphosphonates less than 6 months of screening OR teriparatide less than one year of screening
Being treated with systemic glucocorticoids
Have autoimmune diseases being treated with glucocorticoids or other biologic agents
Enrolled in another clinical trial and receiving treatment with another investigational agent
Pregnant or planning to get pregnant during the study period
Nursing mothers
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note